PT  - JOURNAL ARTICLE
AU  - Mohiedean Ghofrani
AU  - Mary T. Casas
AU  - Robert K. Pelz
AU  - Catherine Kroll
AU  - Natalie Blum
AU  - Scott D. Foster
TI  - Performance characteristics of the ID NOW COVID-19 assay: A regional health care system experience
AID  - 10.1101/2020.06.03.20116327
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.03.20116327
4099  - http://medrxiv.org/content/early/2020/06/05/2020.06.03.20116327.short
4100  - http://medrxiv.org/content/early/2020/06/05/2020.06.03.20116327.full
AB  - Objectives We compared the Abbott ID NOW COVID-19 point-of-care test (POCT) with polymerase chain reaction (PCR)-based methods to assess the claimed sensitivity and specificity of POCT and to optimize test utilization in our regional health care system.Methods Assuming PCR to be the gold standard, we used a convenience sampling of mostly symptomatic COVID-19 suspect hospital patients who had already been tested for internal validation and guideline development purposes by both PCR and POCT to calculate the sensitivity and specificity of POCT with Clopper-Pearson 95% confidence intervals (CI).Results During the study period, 113 paired patient samples met eligibility criteria. The sensitivity of POCT in this population was calculated to be 94.1% [CI 71.31-99.85%] and the specificity was 99.0% [CI 94.33-99.97%].Conclusions Based on the lower sensitivity of POCT and the estimated prevalence of COVID-19 in our symptomatic and asymptomatic hospital patients, we recommend a two-pronged testing approach in which COVID-19 suspect patients are tested by the more sensitive PCR, while asymptomatic patients with a low pre-test probability of infection are tested with POCT supplemented by PCR confirmation of positive results. Furthermore, isolation decisions should not be based on POCT results alone.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PeaceHealth System Institutional Review Board (IRB) has determined this project [1599395-1] is EXEMPT FROM IRB REVIEW according to federal regulations. The IRB is covered under Human Subjects Assurance number FWA 00003906. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data is available upon request.